Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ordesekimab - Amgen

Next Previous
Drug Profile

Ordesekimab - Amgen

Alternative Names: AMG-714; Anti-IL-15 MAB; HuMax anti-IL15; HuMax-IL-15; MAb146B7; PRV-015

Latest Information Update: 27 Nov 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Genmab
  • Developer Amgen; Immune Tolerance Network; National Institute of Allergy and Infectious Diseases; Provention Bio
  • Class Anti-inflammatories; Antirheumatics; Monoclonal antibodies
  • Mechanism of Action Interleukin 15 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Coeliac disease; Inflammation; Lymphoma; Psoriasis; Rheumatoid arthritis; Vitiligo

Most Recent Events

  • 21 Nov 2025 Discontinued - Phase-II for Coeliac disease in Finland, Canada, USA, Netherlands, Spain (SC) (Amgen company communication, November 2025)
  • 21 Nov 2025 Discontinued - Phase-II for Coeliac disease in Finland, Netherlands, Spain, France, USA (IV) (Amgen company communication, November 2025)
  • 21 Nov 2025 Discontinued - Phase-II for Vitiligo in USA (SC) (Amgen company communication, November 2025)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top